ArticleFrontiers in medicine2026
Association of left ventricular geometry with outcomes and treatment response in atrial fibrillation and heart failure with preserved ejection fraction.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06987825 (Chinese Atrial Fibrillation Registry), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chinese Atrial Fibrillation Registry
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Left ventricular (LV) geometric remodeling is a key pathophysiological feature in heart failure with preserved ejection fraction (HFpEF), yet its prognostic implications among patients with concomitant atrial fibrillation (AF) remain unclear. Methods: In this prospective multicenter China-AF cohort study, we categorized baseline LV geometry as normal, eccentric hypertrophy, concentric remodeling, or concentric hypertrophy based on left ventricular mass index (LVMI) and relative wall thickness (RWT). The primary endpoint was a composite of cardiovascular death, thromboembolism, and major bleeding. Secondary outcomes included all-cause death and individual components. Associations were assessed using multivariable Cox regression. Results: A total of 1,691 patients were included, with a median follow-up of 4.8 years. Abnormal LV geometry was present in 50.9% of patients. Concentric remodeling (adjusted HR [aHR] 1.53, 1.17-2.01) and concentric hypertrophy (aHR 1.48, 1.10-1.99) were independently associated with higher primary endpoint risk, with concentric hypertrophy also associated with increased cardiovascular mortality and thromboembolism. Catheter ablation was associated with a lower risk of the primary outcome, with the lowest point estimate observed in the concentric remodeling subgroup (aHR 0.29, 95% CI 0.12-0.74); however, no significant interaction by LV geometry was detected ( Conclusion: LV geometric patterns provide meaningful prognostic stratification in patients with concomitant AF and HFpEF. Concentric remodeling and concentric hypertrophy were associated with higher risks of the primary outcome and cardiovascular mortality, whereas thromboembolic risk was most evident in concentric hypertrophy. The association between catheter ablation and a lower risk of the primary outcome in the concentric remodeling subgroup should be interpreted cautiously, given the observational design and the absence of a significant interaction by LV geometry. Further studies are warranted to validate potential phenotype-guided treatment strategies in this population. Clinical trial registration: URL: clinicaltrials.gov/study/NCT06987825, Identifier NCT06987825.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.